Hand, Foot And Mouth Disease - Pipeline Review, H1 2014

Hand, Foot And Mouth Disease - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Hand, Foot And Mouth Disease - Pipeline Review, H1 2014’, provides an overview of the Hand, Foot And Mouth Disease’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hand, Foot And Mouth Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hand, Foot And Mouth Disease and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hand, Foot And Mouth Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hand, Foot And Mouth Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hand, Foot And Mouth Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hand, Foot And Mouth Disease pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hand, Foot And Mouth Disease
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hand, Foot And Mouth Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hand, Foot And Mouth Disease Overview 6
Therapeutics Development 7
Pipeline Products for Hand, Foot And Mouth Disease - Overview 7
Pipeline Products for Hand, Foot And Mouth Disease - Comparative Analysis 8
Hand, Foot And Mouth Disease - Therapeutics under Development by Companies 9
Hand, Foot And Mouth Disease - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Hand, Foot And Mouth Disease - Products under Development by Companies 14
Hand, Foot And Mouth Disease - Companies Involved in Therapeutics Development 15
Takeda Pharmaceutical Company Limited 15
CJ CheilJedang Corp. 16
Sinovac Biotech Ltd. 17
iQur Ltd. 18
Chongqing Zhifei Biological Products Co., Ltd. 19
Hand, Foot And Mouth Disease - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
EV-71 Vaccine - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
INV-21 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
HFMD Vaccine - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
CJ-40010 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Subunit Vaccine For Hand, Foot And Mouth Disease - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Hand, Foot And Mouth Disease - Recent Pipeline Updates 31
Hand, Foot And Mouth Disease - Product Development Milestones 35
Featured News & Press Releases 35
Apr 24, 2014: Sinovac Receives Notification of China Government Grant for EV71 Vaccine Project 35
Feb 26, 2014: Sinovac's EV71 Vaccine Phase III Clinical Trial Results Published in New England Journal of Medicine 35
May 30, 2013: Sinovac Files New Drug Application For EV71 Vaccine And Receives Filing Acceptance From Beijing Drug Administration 36
May 28, 2013: Experimental Vaccine Protects Kids Against Hand, Foot And Mouth Disease, Clinical Trial Shows 37
Apr 18, 2013: Sinovac Announces Presentation Of EV71 Vaccine Phase III Top-Line Results At 13th Annual World Vaccine Congress & Expo 37
Mar 14, 2013: Sinovac Reports Positive Preliminary Top-Line Results From Phase III Clinical Trial For EV71 Vaccine Candidate Against Hand, Foot and Mouth Disease 38
Jun 25, 2012: Sinovac Reports Progress In EV71 Vaccine Phase III Clinical Trial And Commercialization Preparation Status 39
Jun 11, 2012: Sinovac Reports Progress In EV71 Vaccine Phase III Clinical Trial 40
Mar 29, 2012: Sinovac Announces Publication Of Phase I Clinical Data Of EV71 Vaccine For Prevention Of Hand, Foot And Mouth Disease In Journal Vaccine 40
Mar 11, 2012: Inviragen Reports Top-Line Results From Phase I Trial Of INV21 Vaccine For Treatment Of Hand, Foot And Mouth Disease 41
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 44
Disclaimer 44

List of Tables
Number of Products under Development for Hand, Foot And Mouth Disease, H1 2014 7
Number of Products under Development for Hand, Foot And Mouth Disease - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Late Stage Development, H1 2014 11
Comparative Analysis by Clinical Stage Development, H1 2014 12
Comparative Analysis by Early Stage Development, H1 2014 13
Products under Development by Companies, H1 2014 14
Hand, Foot And Mouth Disease - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 15
Hand, Foot And Mouth Disease - Pipeline by CJ CheilJedang Corp., H1 2014 16
Hand, Foot And Mouth Disease - Pipeline by Sinovac Biotech Ltd., H1 2014 17
Hand, Foot And Mouth Disease - Pipeline by iQur Ltd., H1 2014 18
Hand, Foot And Mouth Disease - Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H1 2014 19
Assessment by Monotherapy Products, H1 2014 20
Number of Products by Stage and Route of Administration, H1 2014 22
Number of Products by Stage and Molecule Type, H1 2014 24
Hand, Foot And Mouth Disease Therapeutics - Recent Pipeline Updates, H1 2014 31

List of Figures
Number of Products under Development for Hand, Foot And Mouth Disease, H1 2014 7
Number of Products under Development for Hand, Foot And Mouth Disease - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Early Stage Products, H1 2014 13
Assessment by Monotherapy Products, H1 2014 20
Number of Products by Top 10 Route of Administration, H1 2014 21
Number of Products by Stage and Top 10 Route of Administration, H1 2014 22
Number of Products by Top 10 Molecule Type, H1 2014 23
Number of Products by Stage and Top 10 Molecule Type, H1 2014 24